Dosimetric investigation of radiation-induced trigeminal nerve toxicity in parotid tumor patients.
parotid cancer
radiotherapy
toxicity
trigeminal neuropathy
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
23
08
2023
received:
15
07
2023
accepted:
14
09
2023
medline:
23
10
2023
pubmed:
23
9
2023
entrez:
23
9
2023
Statut:
ppublish
Résumé
We aimed to describe the association between trigeminal nerve (TN) dose and toxicity and determine a threshold value that leads to TN toxicity in patients with parotid tumors treated with adjuvant conventional fractionated radiation therapy. Eighteen patients who underwent adjuvant radiotherapy (RT) between 2013 and 2018 were included in this retrospective study. TN and its branches were outlined subsequently on the planning CT scans. The doses received by TN were obtained based on the dose-volume histogram. The dose and toxicity relationship was investigated over the total prescribed dose. RT-related toxicity was graded according to Common Terminology Criteria for Adverse Events V4.0 (CTCAEv4.0). The median follow-up was 29.5 months. After RT, 61% of patients had Grade I-II late TN toxicity divided into Grade I in 4 (22%) and Grade II in 7 (39%) patients. TN injury symptoms were as follows: loss of sensation in the chin area in 3, difficulty in jaw movements in 3, and paresthesia in 5 patients. The total RT dose (p = 0.001), Dmax (p = 0.001), PTV-TN Dmax (p = 0.001), D1cc (p = 0.004), D0.5cc (p = 0.001), and D0.1cc (p = 0.01) had a significant effect on TN toxicity. Cut-off values leading to toxicity were determined as 66, 65.5, 65.25, 63.6, and 62.7 Gy for Dmax, PTV-TN Dmax, D0.1cc, D 0.5cc, and D1cc, respectively. Radiation-induced TN injury in head and neck cancer patients may further be investigated in clinically prospective trials by virtue of high toxicity rates with current RT doses in our retrospectively designed dosimetric study in parotid tumors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2907-2914Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Wang X-D, Meng L-J, Hou T-T, Huang SH. Tumours of the salivary glands in northeastern China: a retrospective study of 2508 patients. Br J Oral Maxillofac Surg. 2015;53:132-137.
Wang X, Luo Y, Li M, Yan H, Sun M, Fan T. Management of salivary gland carcinomas-a review. Oncotarget. 2017;8:3946-3956.
NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers. Version 2. 2023.
Hosni A, Huang SH, Goldstein D, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol. 2016;54:75-80.
Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY. Biology and management of salivary gland cancers. Semin Radiat Oncol. 2012;22:245-253.
Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992;69:615-619.
Delaniana S, Lefaixb JL, Pradat PF. Radiation-induced neuropathy in cancer survivors. Radiother Oncol. 2012;105:273-282.
Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg. 2004;20(2):149-152.
Chen AM, Hall W, Guiou M, Mathai M, Vijayakumar S, Purdy JA. Brachial plexopathy after radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;75(3):31-32.
Kong L, Lu JJ, Liss AL, et al. Radiation-induced cranial nerve palsy: a cross sectional study of nasopharyngeal cancer patients after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(5):1421-1427.
Rong X, Tang Y, Chen M, Lu K, Peng Y. Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma. A follow-up study. Strahlenther Onkol. 2012;188(3):282-286.
Bakst RL, Lee N, Pfister DG, et al. Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys. 2011;80(1):148-153.
Luk YS, Shum JS, Sze HC, Chan LL, Ng WT, Lee AW. Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. Oral Oncol. 2013;49(1):49-54.
Anselmo P, Casale M, Arcidiacono F, Trippa F, Rispoli R, Draghini L. Twelve-year results of LINAC-based radiosurgery for vestibular schwannomas. Strahlenther Onkol. 2020;196(1):40-47.
Combs SE, Engelhard C, Kopp C, et al. Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas-pooled results from 3 large German centers. Radiother Oncol. 2015;114(3):378-383.
Litre F, Rousseaux P, Jovenin N, et al. Fractionated stereotactic radiotherapy for acoustic neuromas: a prospective monocenter study of about 158 cases. Radiother Oncol. 2013;106(2):169-174.
Combs SE, Welzel T, Schulz-Ertner D, Huber PE, Debus J. Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2010;76(1):193-200.
Gallogly JA, Jumaily M, Faraji F, Mikulec AA. Stereotactic radiotherapy in three weekly fractions for the management of vestibular schwannomas. Am J Otolaryngol. 2018;39(5):561-566.
Milligan BD, Pollock BE, Foote RL, Link MJ. Long-term tumour control and cranial nerve outcomes following γ knife surgery for larger-volume vestibular schwannomas. J Neurosurg. 2012;116(3):598-604.
Lee NY, Lu JJ, Yu Y. Practical guides in radiation oncology target volume delineation and field setup. In: Lee NY, Lu JJ, Yu Y, eds. A Practical Guide for Conformal and Intensity-Modulated Radiation Therapy. 2nd ed. Springer; 2022:104-113.
Biau J, Dunet V, Lapeyre M, et al. Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. Radiother Oncol. 2019;131:192-201.
Ko HC, Gupta V, Mourad WF, et al. A contouring guide for head and neck cancers with perineural invasion. Pract Radiat Oncol. 2014;4:e247-e258.
Anwar M, Yu Y, Glastonbury CM, El-Sayed IH, Yom SS. Delineation of radiation therapy target volumes for cutaneous malignancies involving the ophthalmic nerve (cranial nerve V-1) pathway. Pract Radiat Oncol. 2016;6:e277-e281.
Common Terminology Criteria for Adverse Events-CTCAEv4.0. Accessed December 23, 2009. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_QuickReference_8.5x11.pdf
Kori SH, Foley KM, Posner JB. Brachial plexus lesions in patients with cancer: 100 cases. Neurology. 1981;31:45-50.
Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol. 1990;18:213-220.
Svensson H, Westling P, Larsson LG. Radiation-induced lesions of the brachial plexus correlated to the dose-time fraction schedule. Acta Radiol Ther Phys Biol. 1975;14:228-238.
Cohen L, Svensson H. Cell population kinetics and dose-time relationships for post-irradiation injury of the brachial plexus in man. Acta Radiol Oncol Radiat Phys Biol. 1978;17:161-166.
Olsen NK, Pfeiffer P, Mondrup K, Rose C. Radiation-induced brachial plexus neuropathy in breast cancer patients. Acta Oncol. 1990;29:885-890.
Yan M, Kong W, Kerr A, Brundage M. The radiation dose tolerance of the brachial plexus: a systematic review and meta-analysis. Clin Transl Radiat Oncol. 2019;18:23-31.
Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29(20):2808-2814. doi:10.1200/JCO.2010.32.4095
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS. RTOG 0522: randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940-2950.
Lee N, Zhang E, Pfister DG, Kim J, Garden AS, Mechalakos J. Phase II study of the addition of bevacizumab to standard chemoradiation for loco-regionally advanced nasopharyngeal carcinoma: radiation therapy oncology group (RTOG) trial 0615. Lancet Oncol. 2012;13(2):172-180.
Thomas TO, Refaat T, Choi M, et al. Brachial plexus dose tolerance in head and neck cancer patients treated with sequential intensity modulated radiation therapy. Radiat Oncol. 2015;10(1):1-8. doi:10.1186/s13014-015-0409-5
Mourad WF, Young BM, Young R, et al. Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. Oral Oncol. 2013;49(9):956-963.